Data from the POLARGO trial potentially establishes a new standard of care for patients with R/R DLBCL ineligible for ...

Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell ...

Data presented at EHA 2025 demonstrated that the Epkinly / R-ICE combination produced an 87% ORR in transplant-eligible r/r ...

Antibody–drug conjugates (ADCs) are a broad class of molecules comprising of a potent cytotoxic agent conjugated with a monoclonal antibody using a chemically stable linker. By selecting a ...

Adding polatuzumab vedotin (Polivy) to standard-of-care treatment significantly improved overall survival (OS) in patients ...

Belimumab may be a safe and effective alternative to rituximab for patients with connective tissue disease–associated immune thrombocytopenia (CTD-ITP) refractory to glucocorticoids and ...

The FDA has approved tafasitamab in combination with lenalidomide and rituximab for adults with relapsed/refractory ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands. Its biosimilar of Roche’s ...

A panelist discusses how immune thrombocytopenia (ITP) is characterized by isolated low platelet counts due to autoimmune destruction, with classification based on duration (acute, extended ...